Analysis of the Safety and Benefit-risk of Ribavirin

Wu Ye,Wu Tao,Zhan Siyan,Guo Xiaoxin,Wang Juan,Wu Ting,Liu Lirong
DOI: https://doi.org/10.3969/j.issn.1005-0698.2006.04.008
2006-01-01
Abstract:Objective: To evaluate the benefit and risk of ribavirin in the treatment of Hepatitis C and the infection of respiratory syncytial virus ( RSV). Method: The safety and benefit-risk of ribavirin were analyzed by means of systematic literature reviews and the use of the national and WHO surveillance databases. Result: Relative databases, websites and medical journals were searched and 581 related literatures were included. The literature review and case-analysis suggested the main adverse effects of ribavin were allergic reactions and blood system disorders while S deaths due to adverse effect were reported. The benefit-risk analysis showed ribavirin was effective in the treatment of Hepatitis C. However, the adverse effects could not be ignored. Especially the teratogenic and embryocidal cases were reported, which suggested the contraindications should be specified. When ribavirin was used in the treatment of RSV infection, the score of benefit was much less than that of risk, which means the usage purpose should be standardized. Conclusion: The main adverse effects of ribavin were allergic reactions and blood system disorders. When combined with interferon and used in treatment of Hepatitis C, ribavirin has more effect than risk but as for the effects of other diseases some further verification is still needed.
What problem does this paper attempt to address?